欧洲药品管理局宣布推荐rVSV-ZEBOV-GP疫苗获得条件性市场许可，这标志着全球首个埃博拉疫苗获得监管批准1。世卫组织对此举表示欢迎，将其视为公共卫生领域的重大突破1。
该疫苗的开发基于2015年西非埃博拉疫情期间在几内亚开展的随机试验1，采用创新的环形接种策略进行评估1。在刚果民主共和国当前疫情中，该疫苗已被用于超过23.6万人的接种工作，其中包括超过6万名卫生和前线工作者1。疫苗的研发得到了包括加拿大政府、挪威外交部、威康基金会、英国政府和无国界医生组织在内的多方资助1。获得许可的疫苗预计将在2020年中期可用1。
The European Medicines Agency has recommended conditional market authorization for the rVSV-ZEBOV-GP vaccine, marking the world's first approved Ebola vaccine 1. The World Health Organization has welcomed this development as a significant breakthrough for public health 1.
The vaccine has already been deployed in the Democratic Republic of the Congo's current outbreak, where it has been administered to more than 236,000 people, including over 60,000 health and frontline workers 1. The candidate underwent clinical evaluation beginning in 2015 during the West African Ebola outbreak in Guinea, employing an innovative ring vaccination strategy 1. The vaccine's development has been supported by funding from the Canadian government, Norway's Ministry of Foreign Affairs, the Wellcome Trust, the British government, and Médecins Sans Frontières 1. The licensed vaccine is expected to become available by mid-2020 1, while eight additional vaccine candidates continue to undergo clinical assessment 1.
评论
还没有评论，欢迎留下第一条。